<DOC>
	<DOCNO>NCT00312208</DOCNO>
	<brief_summary>Primary objective : - To compare disease-free survival treatment docetaxel combination doxorubicin cyclophosphamide doxorubicin cyclophosphamide follow docetaxel operable adjuvant breast cancer HER2neu negative patient positive axillary lymph node . Secondary objective : - To compare toxicity quality life 2 above-mentioned arm . - To evaluate pathologic molecular marker predict efficacy .</brief_summary>
	<brief_title>Docetaxel Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion Criteria : Histologically proven breast cancer . Interval definitive surgery include axillary lymph node dissection registration less equal 60 day . A central pathology review may perform post randomization confirmation diagnosis molecular study . Definitive surgical treatment must either mastectomy , breast conserving surgery axillary lymph node dissection operable breast cancer ( T13 , Clinical N01 , M0 ) . Margins resect specimen definitive surgery must histologically free invasive adenocarcinoma Ductal Carcinoma In Situ ( DCIS ) . Lobular carcinoma insitu count positive margin . Histologic examination tumor : Invasive adenocarcinoma least one axillary lymph node ( pN1 ) show evidence tumor among minimum six resect lymph node . Tumor must show negative HER2 neu protooncogene overexpression FISH ( Fluorescence In Situ Hybridization ) . Confirmation non overexpression centrally assess authorize BCIRG ( Breast Cancer International Research Group ) laboratories prior randomization . Estrogen and/or progesterone receptor analysis perform primary tumor prior randomization . Results must know time randomization . ( Note : Patients whose tumor estrogen receptor negative progesterone receptor status unknown undetermined , must progesterone receptor assayed order determine hormonal receptor status . Patients whose tumor progesterone receptor negative estrogen receptor status unknown undetermined , must estrogen receptor assayed order determine hormonal receptor status ) . Karnofsky Performance status index &gt; 80 % . Normal cardiac function must confirm LVEF ( Lef Ventricular Ejection Fraction ) i.e . MUGA ( Multi Gated Acquisition ) scan echocardiography ECG within 3 month prior registration . LVEF result must equal low limit normal institution . The ECG result must within normal limit show significant abnormality . Laboratory requirement : ( within 14 day prior registration ) Hematology : Neutrophils &gt; = 2.0 x 10^9/L Platelets &gt; = 100 x 10^9/L Hemoglobin &gt; = 10 g/dL Hepatic function : Total bilirubin &lt; = 1 UNL ( Upper Normal Limit ) ASAT ( Aspartate Amino Transferase ) ALAT ( Alanine Amino Transferase ) &lt; = 2.5 UNL Alkaline phosphatase &lt; = 5 UNL Patients ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . Renal function : Creatinine &lt; = 175 Âµmol/L ( 2 mg/dL ) ; If limit reach , calculate creatinine clearance &gt; = 60mL/min . Complete stag workup within 3 month prior registration . All patient contralateral mammography , chest Xray ( Posteroanterior lateral ) and/or CT scan and/or MRI ( Magnetic Resonance Imaging ) , abdominal ultrasound and/or CT scan ( computerized tomography ) and/or MRI , bone scan . In case positive bone scan , bone Xray mandatory rule possibility nonmetastatic hot spot . Other test may perform clinically indicate . Negative pregnancy test ( urine serum ) within 7 day prior registration woman childbearing potential . Exclusion Criteria : Prior systemic anticancer therapy breast cancer ( immunotherapy , hormonotherapy , genetherapy , chemotherapy ) . Prior anthracycline therapy taxoids ( paclitaxel , docetaxel ) malignancy . Prior radiation therapy breast cancer . Bilateral invasive breast cancer . Pregnant , lactate patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure study treatment ( chemotherapy tamoxifen therapy ) must negative urine serum pregnancy test within 7 day prior registration . Any T4 N2 know N3 M1 breast cancer . Preexisting motor sensory neurotoxicity severity &gt; grade 2 NCICTC ( National Cancer Institute Common Toxicity Criteria ) , version 2.0 . Other serious illness medical condition : congestive heart failure unstable angina pectoris , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension highrisk uncontrolled arrhythmias history significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent active uncontrolled infection active peptic ulcer , unstable diabetes mellitus Past current history neoplasm breast carcinoma , except : curatively treat nonmelanoma skin cancer carcinoma situ cervix cancer curatively treat evidence disease least 10 year ipsilateral ductal carcinoma insitu ( DCIS ) breast lobular carcinoma insitu ( LCIS ) breast Chronic treatment corticosteroid unless initiate &gt; 6 month prior study entry low dose ( &lt; 20 mg methylprednisolone equivalent ) . Concurrent treatment ovarian hormonal replacement therapy . Prior treatment stop study entry . Definite contraindication use corticosteroid . Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry . Concurrent treatment anticancer therapy . Current therapy hormonal agent raloxifene , tamoxifen selective estrogen receptor modulators ( SERMs ) , either osteoporosis prevention . Patients must discontinue agent prior randomization . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>